Platelet Aggregation
Conditions
Keywords
dipyrone, platelet aggregation, neuraxial blockage, ibuprofen, platelet aggregation under dipyrone compared to ibuprofen, acetaminophen and parecoxib/valdecoxib, neuraxial blockage in patients receiving ibuprofen is critical in special circumstances, but traditionally not fpr dipyrone
Brief summary
Dipyrone is suggested to inhibit the platelet aggregation comparable to th effect of traditional analgetic substances like Ibuprofen. To verify this hypothesis the investigators conducted the study in comparing patients undergoing traumatologic, visceral or plastic surgical procedures. The investigators randomized them to four groups receiving common analgetic doses of either dipyrone, acetaminophen (paracetamol) or valdecoxib/parecoxib. The investigators took blood samples before initiation of the study drug, 1h, 4hs and 24hs after first intake. The investigators compared the aggregation via aggregometry of platelet rich plasma.
Interventions
40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
DRUGdipyrone
Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
DRUGIbuprofen
Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
DRUGAcetaminophen
Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
OTHERBlood samples
Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
Sponsors
Pfizer
Ruhr University of Bochum
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Planned traumatologic, orthopedic, visceral or plastic surgical procedures
Exclusion criteria
* Prior intake of drugs with effect on the platelet aggregation * Patients with diseases of the gastrointestinal systems * Patients with cardiac or circulatory diseases * Patients receiving corticoids * Patients with cold or asthma * ASA-classification \> 3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of aggregation in platelet rich plasma fter 24 hours of treatment with analgetic doses | 24 hours |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of aggregation of platelet rich plasma 1hour and 4 hours after initiation of study drug | 4 hours |
Countries
Germany
Outcome results
None listed